news
Aspirin for pregnant sickle cell patients needs global context
A new Lancet Global Health correspondence calls out a gap in sickle cell disease (SCD) guidelines for pregnant women. Most evidence comes from high-income countries, while 85% of births affected by SCD are in sub-Saharan Africa. This means current recommendations might not fit where they're needed most.
A new Lancet Global Health correspondence calls out a gap in sickle cell disease (SCD) guidelines for pregnant women. Most evidence comes from high-income countries, while 85% of births affected by SCD are in sub-Saharan Africa. This means current recommendations might not fit where they're needed most.
The architecture take
This isn't just about aspirin; it's a glaring spotlight on how medical 'best practices' often miss the real-world context. We're talking about a disease that disproportionately affects people in specific geographies, yet the research driving treatment guidelines comes from places where healthcare access is entirely different. It means that while a low-dose aspirin might reduce preeclampsia risk, getting that aspirin to someone in rural Nigeria, or even just regular antenatal care, is a whole other beast. The mechanism (reducing inflammation and improving blood flow) is sound, but the delivery system is broken if you can't even get eyes on the patient early enough. This kind of disconnect means policy designed in one place can actively harm in another, or at the very least, remain entirely useless. We need to watch how major bodies like WHO start pushing for geographically relevant research and implementation strategies, not just blanket guidelines.